Candel Therapeutics/$CADL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Candel Therapeutics
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
- Ticker
- $CADL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Needham, United States
- Website
- www.candeltx.com
CADL Metrics
BasicAdvanced
$637M
-
-$1.44
-0.50
-
Price and volume
Market cap
$637M
Beta
-0.5
52-week high
$14.00
52-week low
$4.35
Average daily volume
963K
Financial strength
Current ratio
16.094
Quick ratio
15.89
Long term debt to equity
0.389
Total debt to equity
0.393
Interest coverage (TTM)
-15.26%
Profitability
EBITDA (TTM)
-71.303
Management effectiveness
Return on assets (TTM)
-28.64%
Return on equity (TTM)
-81.84%
Valuation
Price to book
5.03
Price to tangible book (TTM)
5.03
Price to free cash flow (TTM)
-8.953
Free cash flow yield (TTM)
-11.17%
Free cash flow per share (TTM)
-0.93
Growth
Earnings per share change (TTM)
175.63%
3-year earnings per share growth (CAGR)
8.93%
What the Analysts think about CADL
Analyst ratings (Buy, Hold, Sell) for Candel Therapeutics stock.
Analyst projections of the future price of Candel Therapeutics stock.
Bulls say / Bears say
Aglatimagene met the primary endpoint in a 745-patient Phase 3 prostate cancer trial, reducing the risk of disease-free survival events versus placebo plus radiotherapy. Publication in The Lancet Oncology adds peer-reviewed support to Candel’s planned regulatory filing. (Financial Times)
A Phase 2a study in advanced lung cancer reported median overall survival of 24.5 months in its evaluable population, encouraging evidence for a second potential use of aglatimagene. Candel has begun a pivotal Phase 3 trial to test the treatment against docetaxel. (GlobeNewswire, Candel Therapeutics)
Candel had $201.6 million in cash at the end of June and expects it to fund its current plan into the first quarter of 2028. It is also preparing for a potential 2027 prostate cancer launch, giving it time to advance trials and commercial readiness before needing fresh funding. (GlobeNewswire)
Aglatimagene is not yet approved: Candel is still aiming to file its prostate cancer application in the fourth quarter, and any 2027 launch depends on FDA approval. Regulatory review and commercial execution remain important hurdles. (GlobeNewswire)
The lung cancer survival result comes from a Phase 2a study, while the confirmatory Phase 3 trial has only just started. Its randomised comparison with docetaxel must establish whether the encouraging earlier result holds up. (GlobeNewswire, Candel Therapeutics)
Candel has no product-sale revenue and says it will need additional capital to fund commercialisation and its clinical programmes. Its current cash is forecast to last only into Q1 2028, leaving financing and potential dilution risk as spending rises. (Publicnow, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
CADL Financial Performance
Revenues and expenses
CADL Earnings Performance
Company profitability
Upcoming events
No upcoming events
CADL News
AllArticlesVideos
Funds containing CADL
Fund name | Fund size | $CADL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.